BYSI BeyondSpring

BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans

BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
EN
12/10/2020

Underlying

BYSIBeyondSpring

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BeyondSpring

 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Co...

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in , held February 10-12, 2026 in Boston, MA. Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1/PD-LD blockade and highlight Plinabulin’s unique mechanism of action and clinical devel...

February 9, 2026 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxe...

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC. FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immun...

December 12, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing ...

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC patients. Supported by anti-cancer efficacy and safety in signi...

December 11, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides...

BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update Two SITC 2025 presentations: First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC patients who had progressed after PD-1/L1 inhibitors with disease control rate of 85% in combination with docetaxel and Keytruda. Mechanism studies with MD Anderson collaborators showed DC maturation and M1 macrophage polarization via a Plinabulin specific GEF-H1 dependent mechanism in responding patients with Plinabulin, PD-1 inhibitor and radiation. SEED, co-fou...

November 12, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provide...

BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment ASCO 2025 presentation: First-in-class agent Plinabulin drives immune re-sensitization in NSCLC patients progressed to PD-1/L1 therapiesMed (Cell Press) Publication with MD Anderson Collaboration highlights Plinabulin’s rapid dendritic cell activation in responding patients across eight cancer types who failed prior immunotherapySEED Therapeutics’ RBM39 degrader ST-01156 clears FDA IND and advances toward Phase 1...

August 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch